Highlights

• Mesoblast completed enrolment of at least 300 patients in its Phase 3 MSB-DR004 chronic low back pain trial, with top-line results expected in mid-2027.

• Founder and CEO Silviu Itescu exercised 1,885,334 options at A$1.45 per share, investing approximately A$2.73 million and increasing his holding.

• Ryoncil generated US$30.3 million in net revenue during the March 2026 quarter, supporting the company’s commercial transition following US approval.

• Mesoblast held US$121.8 million in cash at 31 March 2026, while continuing to manage debt obligations and expansion costs.

• Mesoblast shares traded at A$2.06, rising 3.74% (+A$0.080), with investors monitoring Ryoncil growth and future clinical milestones. Closed on 28 July 2026.

Mesoblast Ltd (ASX:MSB) is entering a new stage of development as its commercial business begins scaling alongside progress across its late-stage clinical pipeline.

The completion of enrolment in the pivotal chronic low back pain trial removes a major execution milestone, while the exercise of options by founder and chief executive Silviu Itescu highlights continued management alignment.

However, the investment outlook remains dependent on two separate timelines: near-term commercial growth from Ryoncil and longer-term clinical outcomes from rexlemestrocel-L.

Phase 3 Back-Pain Trial Reaches Enrolment Milestone

Mesoblast confirmed completion of enrolment for its MSB-DR004 Phase 3 chronic low back pain trial.

The study includes at least 300 patients receiving a single intra-discal injection of rexlemestrocel-L or a sham control, with participants followed for 12 months.

The primary endpoint is a reduction in chronic low back pain, while secondary measures include physical function, quality of life improvements and reduction in pain medication use.

The trial represents a major opportunity for Mesoblast because chronic low back pain is a significantly larger potential market than the company’s existing rare disease focus.

Rexlemestrocel-L has received Regenerative Medicine Advanced Therapy designation for this indication, which may provide regulatory advantages during future review processes.

However, the designation does not reduce the requirement to demonstrate clinical effectiveness.

CEO Option Exercise Highlights Management Commitment

Mesoblast founder and CEO Silviu Itescu exercised 1,885,334 options at A$1.45 per share on 17 July 2026.

The transaction required an investment of approximately A$2.73 million and increased his holding to 80.84 million shares.

The options were due to expire on 19 July 2026, meaning the exercise was linked to the expiry timeline rather than an open-market purchase.

Nevertheless, the transaction represents a meaningful personal investment and increases alignment between management and shareholders.

The company highlighted that Dr Itescu chose to fund the exercise rather than allow the options to lapse.

Ryoncil Commercial Launch Remains Key Revenue Driver

Mesoblast’s near-term financial performance is increasingly linked to Ryoncil, its first approved product.

Ryoncil received US regulatory approval in December 2024 for the treatment of steroid-refractory acute graft-versus-host disease in children aged two months and older.

During the March 2026 quarter, Ryoncil generated US$30.3 million in net revenue, supported by commercial expansion in the United States.

The company had previously guided FY26 Ryoncil revenue of US$110 million to US$120 million.

Commercial execution remains focused on expanding transplant centre adoption, improving payer coverage and increasing product utilisation.

Financial Position Supports Expansion

Mesoblast reported US$121.8 million in cash at 31 March 2026.

The company recorded net operating cash outflow of US$4.1 million during the March quarter, with year-to-date operating cash outflow reaching US$34.6 million.

The company’s cash position reflects a combination of commercial revenue growth and continued investment into clinical programs.

Mesoblast continues to manage debt obligations, including NovaQuest financing and shareholder-director funding arrangements.

The balance between Ryoncil revenue growth, research spending and debt repayments will remain important for future financial flexibility.

Pipeline Expansion Beyond Ryoncil

While Ryoncil provides the company’s commercial foundation, Mesoblast continues developing additional cell therapy programs.

Rexlemestrocel-L is being evaluated in chronic low back pain and has potential application in broader regenerative medicine markets.

The company is also progressing Revascor for chronic heart failure with reduced ejection fraction and exploring additional applications in inflammatory and degenerative diseases.

The chronic low back pain opportunity is particularly important because it could expand Mesoblast’s addressable market beyond rare disease indications.

A successful outcome would significantly change the company’s commercial profile.

Why the Development Matters

Completing enrolment in the Phase 3 trial reduces one of the key execution risks associated with clinical development.

Large-scale randomised trials often face delays due to patient recruitment challenges, particularly in complex conditions requiring long follow-up periods.

The milestone allows Mesoblast to focus on trial completion, data analysis and potential regulatory preparation.

However, investors must wait until mid-2027 for the primary outcome, leaving Ryoncil sales performance as the main near-term driver.

Growth Catalysts to Watch

Potential catalysts for Mesoblast include:

• Continued growth in Ryoncil sales and expansion across US transplant centres.

• Progress towards broader commercial adoption and payer coverage.

• Top-line results from the MSB-DR004 chronic low back pain Phase 3 trial in mid-2027.

• Regulatory progress for Revascor and other pipeline programs.

• Additional revenue growth from approved and future cell therapy products.

Risks and Challenges

Clinical risk remains the most important long-term challenge.

Although Mesoblast has achieved important milestones, previous clinical programs have experienced setbacks, demonstrating the uncertainty associated with cell therapy development.

The chronic low back pain trial also faces challenges associated with placebo effects and patient-reported pain outcomes.

Commercial execution is another risk. Ryoncil revenue growth depends on transplant centre adoption, reimbursement coverage and physician uptake.

Financial risks remain relevant due to ongoing research investment and debt obligations. Higher-than-expected spending or slower commercial growth could require additional funding.

What Investors Should Watch Next

The next phase of Mesoblast’s progress will focus on commercial execution and clinical advancement.

Key areas to monitor include:

• Ryoncil quarterly revenue growth.

• Operating cash flow and closing cash balance.

• Expansion of transplant centre coverage.

• Progress towards MSB-DR004 trial completion.

• Regulatory developments across the broader pipeline.

Conclusion

Mesoblast has reached an important milestone by completing enrolment in its Phase 3 chronic low back pain trial while continuing to build its commercial foundation through Ryoncil.

The company now has an approved product generating revenue and a late-stage pipeline that could significantly expand its future market opportunity.

However, the investment case remains dependent on execution across two fronts: converting Ryoncil into sustainable commercial growth and delivering successful clinical outcomes from its pipeline.

With shares trading at A$2.06, up 3.74% (+A$0.080), investors are focused on whether Mesoblast can translate its scientific platform into long-term commercial value. Closed on 28 July 2026.